RTP Mobile Logo
Key Questions and Emerging Research in the Management of Chronic Lymphocytic Leukemia and Follicular Lymphoma (Webinar Video Proceedings)
Released October 2020

Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Jeff Sharman and Julie M Vose. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).

    LEARNING OBJECTIVES

    • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed or relapsed/refractory (R/R) CLL, considering clinical presentation and biomarker profile.
    • Evaluate existing and emerging clinical research data to formulate therapeutic recommendations for patients with newly diagnosed or R/R FL.
    • Compare and contrast the efficacy and safety of approved PI3 kinase inhibitors in the treatment of FL.
    • Design and implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for CLL and FL to support quality of life and continuation of treatment.
    • Assess the ongoing clinical trials evaluating other novel investigational approaches for CLL and FL, and obtain consent from appropriate patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jeff Sharman, MD
    Willamette Valley Cancer Institute and Research Center
    Medical Director of Hematology Research
    US Oncology
    Eugene, Oregon

    Advisory Committee, Consulting Agreements and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc.

    Julie M Vose, MD, MBA
    Neumann M and Mildred E Harris Professor
    Chief, Division of Hematology/Oncology
    Nebraska Medical Center
    Omaha, Nebraska

    Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Allogene Therapeutics, Celgene Corporation, Epizyme, Legend Biotech,  Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Vaniam Group, Verastem Inc, Wugen; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Incyte Corporation, Kite, A Gilead Company, Novartis, Seagen Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Kite, A Gilead Company, Seagen Inc and Verastem Inc.

    Release date: October 2020
    Expiration date: October 2021

Acknowledge and close

Watch video
(WIFI is recommended for best performance):